Nappi C, Petraglia F, Di Carlo C, De Rosa R, Zaccardo A, Genazzani A R, Montemagno U
Department of Obstetrics and Gynecology, Second School of Medicine, University of Naples, Italy.
Gynecol Obstet Invest. 1989;27(1):38-41. doi: 10.1159/000293613.
The luteinizing hormone (LH) response to metoclopramide (MCP), a dopamine receptor antagonist, and naloxone (NAL), an opioid receptor antagonist, was evaluated in 7 patients with polycystic ovarian disease (PCOD) before and during treatment with purified human urinary follicle-stimulating hormone (hFSH), and in 6 control women during spontaneously ovulating cycles. Before treatment, in all patients both MCP and NAL administration did not increase plasma LH levels. In the 6 subjects ovulating following hFSH treatment the LH response to MCP and NAL at preovulatory and midluteal phases was restored, as it occurred in control women. Our results suggest that in PCOD the dopamine and opioid activity in the hypothalamus are decreased. The reversal of peripheral ovarian response induced by treatment for the induction of ovulation may restore these impaired neuroendocrine activities.
在7例多囊卵巢疾病（PCOD）患者接受纯化人尿促卵泡激素（hFSH）治疗之前和治疗期间，以及6例处于自然排卵周期的对照女性中，评估了促黄体生成素（LH）对多巴胺受体拮抗剂甲氧氯普胺（MCP）和阿片受体拮抗剂纳洛酮（NAL）的反应。治疗前，所有患者给予MCP和NAL均未增加血浆LH水平。在hFSH治疗后排卵的6名受试者中，LH对MCP和NAL在排卵前和黄体中期的反应恢复，如同在对照女性中发生的那样。我们的结果表明，在PCOD中，下丘脑的多巴胺和阿片样物质活性降低。诱导排卵治疗引起的外周卵巢反应的逆转可能恢复这些受损的神经内分泌活动。
